240 related articles for article (PubMed ID: 17589370)
1. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep.
Haney M; Gunderson EW; Rabkin J; Hart CL; Vosburg SK; Comer SD; Foltin RW
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):545-54. PubMed ID: 17589370
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study.
Bedi G; Foltin RW; Gunderson EW; Rabkin J; Hart CL; Comer SD; Vosburg SK; Haney M
Psychopharmacology (Berl); 2010 Dec; 212(4):675-86. PubMed ID: 20824270
[TBL] [Abstract][Full Text] [Related]
3. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood.
Haney M; Rabkin J; Gunderson E; Foltin RW
Psychopharmacology (Berl); 2005 Aug; 181(1):170-8. PubMed ID: 15778874
[TBL] [Abstract][Full Text] [Related]
4. Marijuana withdrawal in humans: effects of oral THC or divalproex.
Haney M; Hart CL; Vosburg SK; Nasser J; Bennett A; Zubaran C; Foltin RW
Neuropsychopharmacology; 2004 Jan; 29(1):158-70. PubMed ID: 14560320
[TBL] [Abstract][Full Text] [Related]
5. Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Haney M
J Clin Pharmacol; 2002 Nov; 42(S1):34S-40S. PubMed ID: 12412834
[TBL] [Abstract][Full Text] [Related]
6. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
[TBL] [Abstract][Full Text] [Related]
7. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.
Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H
Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159
[TBL] [Abstract][Full Text] [Related]
9. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Haney M; Cooper ZD; Bedi G; Vosburg SK; Comer SD; Foltin RW
Neuropsychopharmacology; 2013 Jul; 38(8):1557-65. PubMed ID: 23443718
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral THC maintenance on smoked marijuana self-administration.
Hart CL; Haney M; Ward AS; Fischman MW; Foltin RW
Drug Alcohol Depend; 2002 Aug; 67(3):301-9. PubMed ID: 12127201
[TBL] [Abstract][Full Text] [Related]
11. Acute and residual mood and cognitive performance of young adults following smoked cannabis.
Matheson J; Mann RE; Sproule B; Huestis MA; Wickens CM; Stoduto G; George TP; Rehm J; Le Foll B; Brands B
Pharmacol Biochem Behav; 2020 Jul; 194():172937. PubMed ID: 32360692
[TBL] [Abstract][Full Text] [Related]
12. Marijuana's dose-dependent effects in daily marijuana smokers.
Ramesh D; Haney M; Cooper ZD
Exp Clin Psychopharmacol; 2013 Aug; 21(4):287-93. PubMed ID: 23937597
[TBL] [Abstract][Full Text] [Related]
13. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.
Vandrey R; Stitzer ML; Mintzer MZ; Huestis MA; Murray JA; Lee D
Drug Alcohol Depend; 2013 Feb; 128(1-2):64-70. PubMed ID: 22921474
[TBL] [Abstract][Full Text] [Related]
14. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.
Hart CL; Ward AS; Haney M; Comer SD; Foltin RW; Fischman MW
Psychopharmacology (Berl); 2002 Dec; 164(4):407-15. PubMed ID: 12457271
[TBL] [Abstract][Full Text] [Related]
15. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Foltin RW
Psychopharmacology (Berl); 2008 Mar; 197(1):157-68. PubMed ID: 18161012
[TBL] [Abstract][Full Text] [Related]
16. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS.
Lutge EE; Gray A; Siegfried N
Cochrane Database Syst Rev; 2013 Apr; (4):CD005175. PubMed ID: 23633327
[TBL] [Abstract][Full Text] [Related]
17. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.
Hart CL; Haney M; Vosburg SK; Comer SD; Foltin RW
Psychopharmacology (Berl); 2005 Sep; 181(2):237-43. PubMed ID: 15830233
[TBL] [Abstract][Full Text] [Related]
18. Abstinence symptoms following oral THC administration to humans.
Haney M; Ward AS; Comer SD; Foltin RW; Fischman MW
Psychopharmacology (Berl); 1999 Feb; 141(4):385-94. PubMed ID: 10090646
[TBL] [Abstract][Full Text] [Related]
19. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.
Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA
J Anal Toxicol; 2013; 37(1):11-6. PubMed ID: 23074216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
